Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SOB100
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : China Medical University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
World's First HLA-G Targeted Exosome Therapy for Cancer Enters U.S. Clinical Trials
Details : The novel platform, named SOB100, has completed preclinical studies and demonstrated promising efficacy in treating aggressive cancers such as breast cancer and glioblastoma.
Product Name : SOB100
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 09, 2025
Lead Product(s) : SOB100
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : China Medical University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable